ArticleDiscover oncology2025
Development of a metabolism-associated prognostic risk model based on immune landscape stratification in prostate cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid Metabolic Rewiring During Continuous Prostate Cancer Progression Defines a Biologically Relevant Four-Gene Prognostic Signature.Biological procedures online · 2026Article
- Tumor innervation and mitochondrial transfer in the cancer pathogenesis: perspectives on genitourinary malignancies.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic reprogramming and immune landscape remodeling are hallmarks of prostate cancer (PCa) progression and therapy resistance. However, the interplay between tumor metabolism, immune infiltration, and prognosis remains poorly characterized.
methodsWe obtained transcriptomic and clinical data of PCa patients from The Cancer Genome Atlas (TCGA). Single-sample gene set enrichment analysis (ssGSEA) was used to assess metabolic pathway activity and define metabolic subtypes. Immune infiltration was evaluated using multiple algorithms, including CIBERSORT and xCell. Prognostic genes were identified through univariate Cox and LASSO regression analyses, and a metabolic risk model was constructed and validated. Functional enrichment, immune checkpoint expression, and clinical associations were further analyzed. A nomogram was developed by integrating clinical features and risk scores.
resultsTwo distinct metabolic subtypes-Metabolism_H and Metabolism_L-were identified, exhibiting differential metabolic activity, immune infiltration, and clinical outcomes. The Metabolism_H group showed upregulation of lipid and amino acid metabolism pathways and was associated with an immunosuppressive microenvironment and worse prognosis. A robust metabolic risk score derived from 14 prognostic genes significantly stratified patients by overall survival (p < 0.001). The risk score positively correlated with PD-L1 expression and immune exclusion features. The integrated nomogram demonstrated strong predictive power for 1-, 3-, and 5-year survival (AUC > 0.74) and good calibration.
conclusionOur findings highlight the metabolic and immunological heterogeneity of prostate cancer and provide a novel metabolism-based prognostic model. Targeting tumor metabolism may enhance immune responses and improve risk stratification and therapeutic outcomes in PCa patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.